LGD-4033
Also known as: Ligandrol, VK5211
LGD-4033 is a nonsteroidal selective androgen receptor modulator designed to stimulate androgen receptor signaling with tissue-selective intent. Human phase 1 data show pharmacokinetic and lean-mass signals, but long-term safety and real-world performance use remain unresolved.
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.
The journals of gerontology. Series A, Biological sciences and medical sciences · 2013 · PMID 22459616
Phase 2 trials completed for muscle wasting. Dose-dependent lean mass gain and HPG suppression documented in healthy men at 1 mg/day.
HPG suppression is dose-dependent but present even at 1 mg/day. Post-cycle therapy recommended.
Off-cycle: 8 weeks
Half-life ~24-36 hours.
Contraindications
- • Liver disease
- • Cardiovascular disease
- • Prostate cancer
- • Pregnancy
Common side effects
- • HPG axis suppression (dose-dependent)
- • Fatigue
- • Mild headache
- • HDL reduction
Serious risks
- • Hepatotoxicity — case reports in literature
- • Testosterone suppression
- • Lipid profile deterioration
Drug interactions
- • Avoid with other hepatotoxic compounds
Requires monitoring
- • Liver function (ALT/AST)
- • Total and free testosterone
- • Lipid panel
Pregnancy / breastfeeding
Contraindicated
Male
HPG suppression documented even at 1 mg/day in healthy volunteers
Female
Limited female safety data — virilization risk
- Suppression is present even at low doses — not dose-free
- Considered milder than RAD-140 but still hepatotoxic in case reports
- Do not stack with other SARMs
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.